Medical - Vaccine Guide 2022 - 14

Notes
Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2022
For vaccination recommendations for persons ages 19 years or older, see
the Recommended Adult Immunization Schedule, 2022.
Additional information
COVID-19 Vaccination
COVID-19 vaccines are recommended for use within the scope
of the Emergency Use Authorization or Biologics License
Application for the particular vaccine. ACIP recommendations
for the use of COVID-19 vaccines can be found at www.cdc.gov/
vaccines/hcp/acip-recs/vacc-specific/covid-19.html.
CDC's interim clinical considerations for use of COVID-19
vaccines can be found at www.cdc.gov/vaccines/covid-19/clinicalconsiderations/covid-19-vaccines-us.html.
y
Consult relevant ACIP statements for detailed recommendations at
www.cdc.gov/vaccines/hcp/acip-recs/index.html.
y For calculating intervals between doses, 4 weeks = 28 days. Intervals of
≥4 months are determined by calendar months.
yWithin a number range (e.g., 12-18), a dash (-) should be read as
" through. "
y Vaccine doses administered ≤4 days before the minimum age or
interval are considered valid. Doses of any vaccine administered
≥5 days earlier than the minimum age or minimum interval should
not be counted as valid and should be repeated as age appropriate.
The repeat dose should be spaced after the invalid dose by the
recommended minimum interval. For further details, see Table 3-1,
Recommended and minimum ages and intervals between vaccine
doses, in General Best Practice Guidelines for Immunization at
www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html.
y Information on travel vaccination requirements and recommendations
is available at www.cdc.gov/travel/.
y For vaccination of persons with immunodeficiencies, see
Table 8-1, Vaccination of persons with primary and secondary
immunodeficiencies, in General Best Practice Guidelines for
Immunization at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/
immunocompetence.html, and Immunization in Special Clinical
Circumstances (In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds.
Red Book: 2018 Report of the Committee on Infectious Diseases. 31st
Itasca, IL: American Academy of Pediatrics; 2018:67-111).
ed.
y For information about vaccination in the setting of a vaccinepreventable
disease outbreak, contact your state or local health
department.
y The National Vaccine Injury Compensation Program (VICP) is a no-fault
alternative to the traditional legal system for resolving vaccine injury
claims. All routine child and adolescent vaccines are covered by VICP
except for pneumococcal polysaccharide vaccine (PPSV23). For more
information, see www.hrsa.gov/vaccinecompensation/index.html.
Routine vaccination
y ActHIB®, Hiberix®, Pentacel®, or Vaxelis®: 4-dose series (3 dose
primary series at age 2, 4, and 6 months, followed by a booster dose*
at age 12-15 months)
- *Vaxelis® is not recommended for use as a booster dose. A different
Hib-containing vaccine should be used for the booster dose.
y PedvaxHIB®: 3-dose series (2-dose primary series at age 2 and 4
months, followed by a booster dose at age 12-15 months)
Catch-up vaccination
y Dose 1 at age 7-11 months: Administer dose 2 at least 4 weeks later
and dose 3 (final dose) at age 12-15 months or 8 weeks after dose 2
(whichever is later).
y Dose 1 at age 12-14 months: Administer dose 2 (final dose) at least
8 weeks after dose 1.
Dengue vaccination
(minimum age: 9 years)
Routine vaccination
y Age 9-16 years living in dengue endemic areas AND have laboratory
confirmation of previous dengue infection
- 3-dose series administered at 0, 6, and 12 months
y Endemic areas include Puerto Rico, American Samoa, US Virgin Islands,
Federated States of Micronesia, Republic of Marshall Islands, and the
Republic of Palau. For updated guidance on dengue endemic areas
and pre-vaccination laboratory testing see www.cdc.gov/mmwr/
volumes/70/rr/rr7006a1.htm?s_cid=rr7006a1_w and www.cdc.gov/
dengue/vaccine/hcp/index.html
Diphtheria, tetanus, and pertussis (DTaP)
vaccination (minimum age: 6 weeks [4 years
for Kinrix® or Quadracel®])
Routine vaccination
y 5-dose series at age 2, 4, 6, 15-18 months, 4-6 years
- Prospectively: Dose 4 may be administered as early as age
12 months if at least 6 months have elapsed since dose 3.
- Retrospectively: A 4th
dose that was inadvertently administered as
early as age 12 months may be counted if at least 4 months have
elapsed since dose 3.
Catch-up vaccination
y Dose 5 is not necessary if dose 4 was administered at age 4 years or
older and at least 6 months after dose 3.
y For other catch-up guidance, see Table 2.
Special situations
yWound management in children less than age 7 years with history of
3 or more doses of tetanus-toxoid-containing vaccine: For all wounds
except clean and minor wounds, administer DTaP if more than 5 years
since last dose of tetanus-toxoid-containing vaccine. For detailed
information, see www.cdc.gov/mmwr/volumes/67/rr/rr6702a1.htm.
Haemophilus influenzae type b vaccination
(minimum age: 6 weeks)
y Dose 1 before age 12 months and dose 2 before age 15 months:
Administer dose 3 (final dose) at least 8 weeks after dose 2.
y 2 doses of PedvaxHIB® before age 12 months: Administer dose 3
(final dose) at 12-59 months and at least 8 weeks after dose 2.
y 1 dose administered at age 15 months or older: No further doses
needed
y Unvaccinated at age 15-59 months: Administer 1 dose.
y Previously unvaccinated children age 60 months or older who
are not considered high risk: Do not require catch-up vaccination
For other catch-up guidance, see Table 2. Vaxelis® can be used for catchup
vaccination in children less than age 5 years. Follow the catch-up
schedule even if Vaxelis® is used for one or more doses. For detailed
information on use of Vaxelis® see www.cdc.gov/mmwr/volumes/69/
wr/mm6905a5.htm.
Special situations
y Chemotherapy or radiation treatment:
Age 12-59 months
- Unvaccinated or only 1 dose before age 12 months: 2 doses,
8 weeks apart
- 2 or more doses before age 12 months: 1 dose at least 8 weeks after
previous dose
Doses administered within 14 days of starting therapy or during therapy
should be repeated at least 3 months after therapy completion.
y Hematopoietic stem cell transplant (HSCT):
- 3-dose series 4 weeks apart starting 6 to 12 months after successful
transplant, regardless of Hib vaccination history
y Anatomic or functional asplenia (including sickle cell disease):
Age 12-59 months
- Unvaccinated or only 1 dose before age 12 months: 2 doses,
8 weeks apart
- 2 or more doses before age 12 months: 1 dose at least 8 weeks after
previous dose
Unvaccinated* persons age 5 years or older
- 1 dose
y Elective splenectomy:
Unvaccinated* persons age 15 months or older
- 1 dose (preferably at least 14 days before procedure)
y HIV infection:
Age 12-59 months
- Unvaccinated or only 1 dose before age 12 months: 2 doses,
8 weeks apart
- 2 or more doses before age 12 months: 1 dose at least 8 weeks after
previous dose
Unvaccinated* persons age 5-18 years
- 1 dose
y Immunoglobulin deficiency, early component complement
deficiency:
Age 12-59 months
- Unvaccinated or only 1 dose before age 12 months: 2 doses,
8 weeks apart
- 2 or more doses before age 12 months: 1 dose at least 8 weeks after
previous dose
* Unvaccinated = Less than routine series (through age 14 months) OR
no doses (age 15 months or older)
henryschein.com/medical
14
22MS6015

Medical - Vaccine Guide 2022

Table of Contents for the Digital Edition of Medical - Vaccine Guide 2022